ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 1933 • ACR Convergence 2022

    PECOS (Pediatric SARS-CoV-2 MIS-C Long-term Outcomes Study): Preliminary Results

    Gina Montealegre Sanchez1, Roberta DeBiasi2, Lauren Arrigoni2, Kevin Rubenstein3, Jason Liang4, James Bost2, Marcin Gierdalski2, Max Wolff3, Mallory Barrix2, Maureen Edu2, Saira Huq2, Shera Weyers3, Patricia Bandettini5, Dorothy Bulas2, Tom Burklow6, Marcus Chen5, Sanchita Das6, Robin Dewar3, Joseph Fontana5, Ashraf Harahsheh2, Linda Herbert2, Anastassios Koumbourlis2, Andrew Lipton5, Laura Olivieri2, Dinesh Pillai2, Vandana Sachdev5, Craig Sable2, Audrey Thurm7, Evrim Turkbey6, Alexandra Yonts2, Jonathan Zember2, Eric Vilain2, Meghan Delaney2, Luigi Notarangelo4, David Wessel8 and Karyl Barron4, 1NIAID/NIH, Garrett Park, MD, 2Children's National Hospital, Washington, DC, 3Frederick National Laboratory for Cancer Research, Frederick, MD, 4NIAID/NIH, Bethesda, MD, 5NHLBI/NIH, Bethesda, MD, 6CC/NIH, Bethesda, MD, 7NIMH/NIH, Bethesda, MD, 8Children's National Hospital, Washington, MD

    Background/Purpose: The long-term complications of SARS-CoV-2 and MIS-C in children are unknown. PECOS, a joint study at the National Institutes of Health (NIH) Clinical Center…
  • Abstract Number: 1938 • ACR Convergence 2022

    Current Approach to COVID-19 and Other Vaccinations in Children with Previous Multisystem Inflammatory Syndrome (MIS-C): An International Survey

    Francesca Minoia1, Federica Lucioni1, Merav Heshin-Bekenstein2, Sebastiaan Vastert3, Christoph Kessel4, Yosef Uziel5, Lovro Lamot6, Nicola Ruperto7, Marco Gattorno8, Claudia Bracaglia9 and Natasa Toplak10, 1Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy, 2Dana Dwek Children's Hospital, Tel Aviv Medical Center Israel, Binyamina, Israel, 3Pediatric Rheumatology & Immunology, University Medical Center Utrecht, Utrecht, Netherlands, 4Department of Pediatric Rheumatology & Immunology, WWU Medical Center (UKM), Münster, Germany, 5Meir Medical Center, Kfar Saba; Sackler School of Medicine, Tel Aviv University, Kfar Saba, Israel, 6University Hospital Center Zagreb, Zagreb, Croatia, 7IRCCS Istituto Giannina Gaslini; PRINTO, Clinica Pediatrica e Reumatologia, Genova, Italy, 8Pediatric Clinic and Rheumatology Unit, IRCCS Istituto Giannina Gaslini, Genoa, Italy, 9Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesu', Rome, Italy, 10University Children's Hospital, University Medical Centre, Ljubljana, Slovenia

    Background/Purpose: Following the Coronavirus Disease-19 (COVID-19) pandemic outbreaks, the hyperinflammatory condition termed Multisystem Inflammatory Syndrome in Children (MIS-C) has become a healthcare issue worldwide. Since…
  • Abstract Number: 1937 • ACR Convergence 2022

    Adult Rheumatologists’ Knowledge, Comfort Level, and Perceived Barriers in Supporting Newly Transitioned Youth with Chronic Rheumatic Diseases in Canada

    Madhavi Prasad1, Michelle Batthish2, KAREN BEATTIE2 and Roberta Berard1, 1London Health Sciences Centre, London, ON, Canada, 2McMaster University, Hamilton, ON, Canada

    Background/Purpose: Transitioning from pediatric to adult rheumatology care around age 18 is an important and often challenging period in patients' lives. Differences between adult and…
  • Abstract Number: 1940 • ACR Convergence 2022

    Genetic Variants and Cytokine Signatures in Patients with Syndrome of Undifferentiated Recurrent Fevers

    Marci Macaraeg, Michael Matt, Grant Schulert, Elizabeth Baker and Elizabeth Handorf, Cincinnati Children's Hospital Medical Center, Cincinnati, OH

    Background/Purpose: Unexplained, recurrent fevers are a common presentation to pediatric rheumatology and a cause of significant burden to affected families due to days of daycare…
  • Abstract Number: 1941 • ACR Convergence 2022

    Pediatric Idiopathic Pulmonary Hemosiderosis – a Single-Center, Retrospective Study Comparing Use of Commonly Used Steroid-Sparing Agents

    Melissa Argraves1, Melissa Lerman1, Julie Chase2 and Samuel Goldfarb3, 1Children's Hospital of Philadelphia, Philadelphia, PA, 2University of Kentucky, Lexington, KY, 3University of Minnesota, Minneapolis, MN

    Background/Purpose: Idiopathic Pulmonary Hemosiderosis (IPH) is a rare, pediatric predominant condition causing episodic diffuse alveolar hemorrhage, which can be recurrent and life-threatening. Chronic steroid use…
  • Abstract Number: 1932 • ACR Convergence 2022

    Efficacy of the COVID-19 Vaccine in Pediatric Systemic Lupus Erythematosus Patients

    Yi Shi1, Catherine Park2, Sangeeta Sule2 and Sun-Young Ahn2, 1Children's National Hospital, New York, NY, 2Children's National Hospital, Washington, DC

    Background/Purpose: The COVID-19 virus has caused significant morbidity and mortality, despite introduction of the COVID vaccine. Immunocompromised patients have been shown to have reduced response…
  • Abstract Number: 1943 • ACR Convergence 2022

    Prevalence and Evolution of Undifferentiated Periodic Fever Syndromes in an Academic Pediatric Rheumatology Practice

    Jacob Anderson1, Catherine Bingham2, Lisabeth Scalzi3, Natalya Gaffney4, Kimberly Hays5, Brandt Groh2 and Timothy Hahn2, 1Phoenix Children's Hospital, Phoenix, AZ, 2Penn State Children's Hospital, Hershey, PA, 3Penn State Health, Hummelstown, PA, 4Self-Employed, Carlisle, PA, 5Penn State Health, Hershey, PA

    Background/Purpose: Periodic Fever Syndromes (PFS) are common referrals to pediatric rheumatology clinics. While the syndrome of Periodic Fevers, Aphthous stomatitis, Pharyngitis, and Adenitis (PFAPA) is…
  • Abstract Number: 1944 • ACR Convergence 2022

    Description and Delays in Care in the Bridge to Adult Care from Childhood for Young Adults with Rheumatic Disease (BACC YARD) Program, a Pediatric-to-Adult Rheumatology Transition Program

    John Bridges1, Livie Huie2, Amanda Alexander3, Randy Cron2, Maria Danila2, Victoria Gennaro4, Laura Hughes2, Bailey Lipham5, Linda McAllister6, Matthew Mullen7, Annelle Reed4, Daniel Reiff2, Carolyn Smith4, Emily Smitherman2, Matthew Stoll2, Peter Weiser2 and Melissa Mannion2, 1University of Alabama at Birmingham/Children's of Alabama, Birmingham, AL, 2University of Alabama at Birmingham, Birmingham, AL, 3University of Alabama at Birmingham, Homewood, AL, 4Children's of Alabama, Birmingham, AL, 5University of Alabama Medical School, Birmingham, AL, 6Children's of Alabama, Trussville, AL, 7University of Alabama-Birmingham, Vestavia Hills, AL

    Background/Purpose: Children with chronic rheumatic conditions age and require transfer to adult rheumatologists for continued care. The transition period from pediatric to adult-oriented care is…
  • Abstract Number: 1946 • ACR Convergence 2022

    Focused Clinical Correlation of Autoantibody Testing in Juvenile Systemic Sclerosis and Localized Scleroderma Using the Euroimmun™ Scleroderma Disease Profile

    Jonathan Li1, Emily Mirizio2, Katherine Buhler3, Anne Stevens4, May Choi5, Kaila Schollaert-Fitch2, Kathryn Torok2, Christopher Liu2 and Marvin Fritzler3, 1Combined Internal Medicine-Pediatrics Residency Program, Children's Hospital of UPMC, Pittsburgh, PA, 2Pediatric Rheumatology, Children's Hospital of UPMC, Pittsburgh, PA, 3University of Calgary, Calgary, AB, Canada, 4Janssen, Hansville, WA, 5Brigham and Women's Hospital | University of Calgary, Calgary, AB, Canada

    Background/Purpose: Commercially available autoantibody (AAb) panels are developed for adult rheumatological diseases; application to pediatric disease has not been established. As a pediatric scleroderma referral…
  • Abstract Number: 1930 • ACR Convergence 2022

    Assessing the Number of Children Evaluated for Recurrent Fevers During the COVID-19 Pandemic in North America

    Leanne Mansfield1, Sivia Lapidus2, Matthew Hollander3, Julie Cherian4, Marinka Twilt5, Maryam Piram6, Lakshmi Moorthy7, Brian Nolan8, Geraldina Lionetti9, Eveline Wu10, Heather Tory11, Elizabeth Kessler12, Cassyanne Aguiar13, Sirada Panupattanapong14, Shoghik Akoghlanian15, Felice Adler-Shohet16, Melissa Oliver17, Smriti Mohan18, Patricia DeLaMora19, Karen Durrant20, Theresa Wampler Muskardin21, Samira Nazzar22, Mariana Correia Marques23, Matthew Basiaga24, Tiphanie vogel25, Jamie Lai25, Kathryn Edwards26, Kathryn Garguilo26, Sheila Nolan19, Emily Sheboy Scarcello27, Gabrielle Alonzi28, Ann Szymanski29, Joyce Hui-Yuen30, karen onel31, Fatma Dedeoglu32, Maria Gutierrez33, Grant Schulert34 and CARRA PFAPA/Autoinflammatory Working Group N/A35, 1Hospital for Special Surgery/Weill Cornell Medicine, New York, NY, 2Joseph M. Sanzari Children's Hospital Hackensack University Medical Center, Montclair, NJ, 3University of Vermont Medical Center Children's Hospital, Burlington, VT, 4Renaissance School of Medicine at Stony Brook University, Stony Brook Children’s Hospital, Stony Brook, NY, 5Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, 6CHU Sainte Justine, University of Montreal, Montréal, QC, Canada, 7Rutgers-Robert Wood Johnson Medical School, New Brunswick, NJ, 8Ann & Robert H. Lurie Children's Hospital, Chicago, IL, 9UCSF Benioff Children's Hospitals, Oakland, CA, 10University of North Carolina, Chapel Hill, NC, 11Connecticut Children's Medical Center and University of Connecticut School of Medicine, S Glastonbury, CT, 12Spectrum Health Helen DeVos Children's Hospital, Michigan State University, Grand Rapids, MI, 13Children’s Hospital of The King’s Daughters / Eastern Virginia Medical School, Norfolk, VA, 14Cleveland Clinic Children's, Cleveland, OH, 15Division of Rheumatology, Nationwide Children's Hospital and Department of Pediatrics, The Ohio State University, Columbus, OH, 16University of California, Irvine and Children’s Hospital of Orange County, Orange, CA, 17Indiana University School of Medicine, Indianapolis, IN, 18University of Michigan Medical School, Ann Arbor, MI, 19Boston Children's Health Physicians, New York Medical College, Valhalla, NY, 20Autoinflammatory Alliance, San Francisco, CA, 21Colton Center for Autoimmunity, NYU School of Medicine, New York, NY, 22University of California Los Angeles David Geffen School of Medicine, Los Angeles, CA, 23Children's National Health System/National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, MD, 24Mayo Clinic, Inver Grove Heights, MN, 25Baylor College of Medicine, Houston, TX, 26Vanderbilt University Medical Center, Nashville, TN, 27Boston Children's Health Physicians, Valhalla, NY, 28Boston Children's Hospital, Boston, MA, 29Johns Hopkins All Children’s Hospital, St. Petersburg, FL, 30Cohen Children’s Medical Center, Hofstra-Northwell School of Medicine, Feinstein Institutes for Medical Research, Queens, NY, 31Hospital for Special Surgery, New York, NY, 32Division of Immunology, Boston Children's Hospital, Boston, MA, 33Johns Hopkins University School of Medicine, Baltimore, MD, 34Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 35CARRA, Washington, DC

    Background/Purpose: The impact of the COVID-19 pandemic on the number of pediatric patients evaluated in North America for recurrent fevers and autoinflammatory diseases is unknown;…
  • Abstract Number: 1948 • ACR Convergence 2022

    Clinical Characteristics and Outcomes of Pediatric ANCA-Associated Vasculitis Patients: Single-Center Inception Cohort

    Hyun Ho Lee1, Lauren Blazek2 and Eveline Wu3, 1The University of North Carolina Chapel Hill, Chapel Hill, NC, 2UNC Kidney Center, The University of North Carolina Chapel Hill, Chapel Hill, NC, 3University of North Carolina, Chapel Hill, NC

    Background/Purpose: ANCA associated vasculitis (AAV) is a chronic autoimmune disorder characterized by ANCA production and small vessel inflammation and necrosis. ANCA autoantigen targets include myeloperoxidase…
  • Abstract Number: 1949 • ACR Convergence 2022

    Effectiveness of the BNT162b2 mRNA COVID-19 Vaccine Among Adolescents with Juvenile-onset Inflammatory Rheumatic Diseases

    amit ziv1, Merav Heshin-Bekenstein2, Ruby Haviv3, Shaye Kivity4, doron netzer5, shlomit yaron5, yoav schur5, tsipi egert6, yona egert6, yaron sela7, Philip Hashkes8 and Yosef Uziel9, 1Meir Hospital, Kfar Saba, Israel, 2Dana Dwek Children's Hospital, Tel Aviv Medical Center Israel, Binyamina, Israel, 3Meir Medical Center, Ra'Anana, Israel, 4Meir Medical Center, Kefar Saba, Israel, 5Community Medical Services Division, Clalit Health Services, Tel Aviv, Israel, 6Inbar, NPO, Ramat Gan, Israel, 7The Research Center for Internet Psychology, School of Communications, Reichman University, Herzliya, Israel, 8Shaare Zedek Medical Center, Jerusalem, Israel, 9Meir Medical Center, Kfar Saba; Sackler School of Medicine, Tel Aviv University, Kfar Saba, Israel

    Background/Purpose: Effectiveness of the BNT162b2 mRNA COVID-19 vaccine for adolescents with juvenile-onset inflammatory rheumatic diseases (IRD) is unknown. Several studies suggested attenuated immunogenicity in patients…
  • Abstract Number: 1951 • ACR Convergence 2022

    Interleukin 1 Receptor Antagonist Relation to Cardiovascular Disease in Patients with Rheumatoid Arthritis

    Claudia De Luis zarate1, Cristina Almeida Santiago2, Maria Vanesa Hernández Hernández3, antonia De Vera González4, Alejandra González Delgado4, Juan Carlos Quevedo Abeledo5 and Ivan Ferraz Amaro6, 1Hospital Universitario de Canarias, Puerto de la Cruz, Spain, 2Hospital Universitario Dr Negrín, Las Palmas de Gran Canaria, Spain, 3HUC, San Cristóbal de la, Spain, 4HOSPITAL UNIVERSITARIO DE CANARIAS, Santa Cruz de Tenerife, Spain, 5Hospital Universitario Dr. Negrín, Santa Cruz de Tenerife, Spain, 6Division of Rheumatology. Hospital Universitario de Canarias. Spain., Santa Cruz de Tenerife, Spain

    Background/Purpose: Interleukin (IL) 1, and its family member, IL-1 receptor antagonist (IL-1ra), are involved in the pathogenesis and inflammation perpetuation of patients with rheumatoid arthritis…
  • Abstract Number: 1952 • ACR Convergence 2022

    Burden of Disease in Refractory Rheumatoid Arthritis

    Kristin Wipfler1, Bobby Kwanghoon Han2, Urbano Sbarigia3, Federico Zazzetti4, Anna Sheahan5, Iris Lin6, Patricia Katz7, Evo Alemao8 and Kaleb Michaud9, 1FORWARD, The National Databank for Rheumatic Diseases, Omaha, NE, 2Division of Rheumatology, University of Washington, Seattle, WA, 3Johnson & Johnson, Beerse, Belgium, 4Janssen Medical Affairs Global Services, LLC, Buenos Aires, Argentina, 5Janssen Research and Development, Chapel Hill, NC, 6Janssen, Horsham, PA, 7UCSF, San Rafael, CA, 8Janssen, Princeton, NJ, 9University of Nebraska Medical Center, Omaha, NE

    Background/Purpose: Despite major advances in RA treatment and the improved outcomes that have been associated with the expanding number of advanced therapies available, a substantial…
  • Abstract Number: 1947 • ACR Convergence 2022

    Medication Use in Childhood Sjogren Disease

    Erin Treemarcki1, Matthew Basiaga2, Scott Lieberman3 and Sara Stern1, 1University of Utah, Salt Lake City, UT, 2Mayo Clinic, Inver Grove Heights, MN, 3University of Iowa, Iowa City, IA

    Background/Purpose: Childhood Sjogren’s Disease (childSD) is a rare complex chronic autoimmune disease primarily affecting lacrimal and salivary glands. Currently there is a paucity of information…
  • « Previous Page
  • 1
  • …
  • 662
  • 663
  • 664
  • 665
  • 666
  • …
  • 2607
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology